These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15868022)

  • 1. Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies.
    Towse A; Kettler H
    Bull World Health Organ; 2005 Apr; 83(4):301-7. PubMed ID: 15868022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R&D policy, agency costs and innovation in personalized medicine.
    Yin W
    J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness.
    Berndt ER; Glennerster R; Kremer MR; Lee J; Levine R; Weizsäcker G; Williams H
    Health Econ; 2007 May; 16(5):491-511. PubMed ID: 17013993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O; Zhou Y
    Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Market incentives and pharmaceutical innovation.
    Yin W
    J Health Econ; 2008 Jul; 27(4):1060-1077. PubMed ID: 18395277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encouraging the development of new vaccines.
    Grabowski H
    Health Aff (Millwood); 2005; 24(3):697-700. PubMed ID: 15886162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of private-sector contracts for primary health care: theory, evidence and lessons for low-income and middle-income countries.
    Palmer N
    Bull World Health Organ; 2000; 78(6):821-9. PubMed ID: 10916919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding Bioshield: a call for caution.
    May T
    Am J Public Health; 2007 Apr; 97 Suppl 1(Suppl 1):S23-5. PubMed ID: 17413075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance.
    Gilchrist SA; Nanni A
    Health Policy Plan; 2013 Dec; 28(8):838-46. PubMed ID: 23174880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The decline of venture capital investment in early-stage life sciences poses a challenge to continued innovation.
    Fleming JJ
    Health Aff (Millwood); 2015 Feb; 34(2):271-6. PubMed ID: 25646107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is wrong with orphan drug policies?
    Côté A; Keating B
    Value Health; 2012 Dec; 15(8):1185-91. PubMed ID: 23244823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing drugs for developing countries.
    Ridley DB; Grabowski HG; Moe JL
    Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine advance-purchase agreements for low-income countries: practical issues.
    Berndt ER; Hurvitz JA
    Health Aff (Millwood); 2005; 24(3):653-65. PubMed ID: 15886157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The patents-based pharmaceutical development process: rationale, problems, and potential reforms.
    Barton JH; Emanuel EJ
    JAMA; 2005 Oct; 294(16):2075-82. PubMed ID: 16249422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Project BioShield: what it is, why it is needed, and its accomplishments so far.
    Russell PK
    Clin Infect Dis; 2007 Jul; 45 Suppl 1():S68-72. PubMed ID: 17582574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.